Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy—Modified N7 Regimen with Dinutuximab Beta

Cancers(2026)10.3390/cancers18061028Source: DataRank Database

End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy—Modified N7 Regimen with Dinutuximab Beta is a research paper published in Cancers (2026). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

0 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Impact (FWCI 0.00)OA: goldTopics (15)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Calvin P. L. Hoo,Ho Ming Cheung,I. W. C. Wong ORCID,K. F. Kevin Fung,Sylvia L. Y. Chang

Live enrichment

PubMed:41899628 PMC:PMC13025792 OpenAlex:https://openalex.org/W7140082124

FWCI

0.00

Citation Percentile

0.3%

goldLicense: cc-by

journalhttps://www.mdpi.com/2072-6694/18/6/1028/pdf

publisherhttps://www.mdpi.com/2072-6694/18/6/1028/pdf

journalhttps://doi.org/10.3390/cancers18061028

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41899628

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC13025792/

Fields of Study

Neuroblastoma Research and TreatmentsCancer therapeutics and mechanismsCancer Research and Treatments

Keywords

TolerabilityRegimenNeuroblastomaInduction chemotherapyChemoimmunotherapyChemotherapyAdverse effectImmunotherapyHigh-risk NeuroblastomaAnti-gd2Dinutuximab BetaModified N7

Sustainable Development Goals

SDG 0: Good health and well-being

End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy—Modified N7 Regimen with Dinutuximab Beta

FAIR Checklist

Authors (14)

Impact

Open Access

Topics

Annotations (Europe PMC)